Brind.

Royalty Pharma enhanced its governance structure following an acquisition by an external manager.

1 report, 1 independent Updated Jul 17

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Royalty Pharma Warburg Pincus

Keep exploring

The entities involved

Royalty Pharma
biopharmaceutical company based in New York City
- Visteon filed transaction details with the SEC and traded on the Nasdaq stock exchange on June 6, 2026.Sun 17:49
- Royalty Pharma acquired a royalty interest in Amgen's drug Imdelltra.Sun 02:34
Warburg Pincus
private equity firm from USA
- Warburg Pincus initiated a takeover bid for Ingenia Communities Group.Mon 07:26
- Vietnamese leader Lam met with US groups in New York, discussing aviation cooperation with Boeing and seeking investment from firms like Warburg Pincus.Thu 21:20

Related events

Coverage

Newest first; wire copies grouped

Jul 17GlobeNewswireRoyalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company’s Board of Directors Strengthens Board of Directors with appointment of two new independent members, increasing independent r